Prosecution Insights
Last updated: October 02, 2026
Application No. 18/235,751

INTEGRATED FUNCTIONAL AND MOLECULAR PROFILING OF CELLS

Final Rejection §DP
Filed
Aug 18, 2023
Priority
Mar 26, 2015 — provisional 62/138,813 +4 more
Examiner
PRIEST, AARON A
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Houston System
OA Round
3 (Final)
61%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
495 granted / 808 resolved
+1.3% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
45 currently pending
Career history
840
Total Applications
across all art units

Statute-Specific Performance

§101
7.8%
-32.2% vs TC avg
§103
33.0%
-7.0% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
23.3%
-16.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 808 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/14/2026 has been entered. Claims 1-24 are pending and the subject of this Office Action. All claims have been rejoined. Other than the double patenting rejections below, the subject matter of claims 1-24 is allowable over the prior art which fails to teach or suggest “performing a Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) assay on a single cell spatially confined in a nanowell to generate TIMING data, wherein the TIMING data is analyzed by a method comprising performing confinement-constrained cell segmentation and confinement-constrained cell tracking on the single cell.” Double Patenting- Obvious Type - Maintained The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Instant claims 1-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over conflicting claims 1-86 of U.S. Patent No. 10746736. The instant claims are obvious over the conflicting claims because the conflicting claims teach a species of method of performing the same method as here, specifically using TIMING. Instant claims 1-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over conflicting claims 1-17 of U.S. Patent No. 11774449. The instant claims are obvious over the conflicting claims because the conflicting claims teach a species of method of performing the same method as here, specifically using TIMING. Response to Arguments This rejection is maintained because Applicants did not file a terminal disclaimer despite stating they did file a terminal disclaimer. All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Aaron Priest whose telephone number is (571)270-1095. The examiner can normally be reached 8am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AARON A PRIEST/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Aug 18, 2023
Application Filed
Sep 23, 2025
Non-Final Rejection mailed — §DP
Mar 23, 2026
Response Filed
May 12, 2026
Final Rejection mailed — §DP
Sep 14, 2026
Request for Continued Examination
Sep 15, 2026
Response after Non-Final Action
Sep 22, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746539
MULTIPLEXED POLYMERASE CHAIN REACTION IN MICROPIPETTE FORMAT
2y 11m to grant Granted Sep 29, 2026
Patent 12736524
RECEPTORS FOR CYCLIC DINUCLEOTIDES AND METHODS FOR SCREENING AGONISTS OR INHIBITORS THEREOF
2y 11m to grant Granted Sep 15, 2026
Patent 12735744
Compositions and Methods for Detecting C1orf43 Nucleic Acid
2y 7m to grant Granted Sep 15, 2026
Patent 12716104
SAMPLE POOLING ASSAY
2y 7m to grant Granted Aug 25, 2026
Patent 12703885
METHOD FOR PREDICTING THE RESPONSE TO CDK4/6 INHIBITOR THERAPY IN CANCER PATIENTS
3y 1m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
61%
Grant Probability
87%
With Interview (+25.7%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 808 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month